RxDoctor Payments Data

Jill Ballantine, PA

Physician Assistant · Paris, TXNPI 1467691691

Payments from drug & device makers

$2,420in general payments, 2019–2025

Across 137 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$575
  • Novartis$405
  • Johnson & Johnson$395
  • Pfizer$251
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$229
  • Sanofi-aventis U.S. LLC$80
  • plus $485 from 14 others

What the payments were for

  • Food & beverage$2,420100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,420 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$112,104
Medicare patients
697
Services billed
1,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban265$247,077
XareltoRivaroxaban106$97,560
EntrestoSacubitril/Valsartan66$70,200
BrilintaTicagrelor28$22,187
Repatha SureclickEvolocumab30$19,411
JardianceEmpagliflozin22$14,786
FarxigaDapagliflozin Propanediol24$14,480
MultaqDronedarone Hcl17$13,897
VascepaIcosapent Ethyl12$11,674
Praluent PenAlirocumab21$10,171
Metoprolol Succinate368$5,628
Ranolazine ErRanolazine83$5,151
Bisoprolol Fumarate151$3,887
Isosorbide Dinitrate117$3,430
Atorvastatin Calcium321$3,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$251$247,077265 claims
Johnson & JohnsonXarelto$395$97,560106 claims
NovartisEntresto$405$70,20066 claims
AstraZenecaBrilinta, Farxiga$68$36,66752 claims
Boehringer IngelheimJardiance$29$14,78622 claims
Sanofi-aventis U.S. LLCMultaq$80$13,89717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Paris

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →